Document is current
Any future updates will be listed below
-
Authors
Buse, Dawn C.
Lipton, Richard B.
Urman, Robert
Vaidya, Shruti J.
Robinson, Sarah C.
Jacobson, Alice S.
Scott, Alexandra B.
Bensink, Mark E.
Pressman, Alice R. https://orcid.org/0000-0003-2775-3275
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 2 August 2025
Accepted: 25 November 2025
First Online: 17 December 2025
Declarations
:
: Dawn C. Buse: research support from the US Food and Drug Administration (FDA) and the National Headache Foundation; consultant, advisory board member, or honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Novartis, Teva, and Theranica. Richard B. Lipton: research support from the National Institutes of Health, US FDA, and the National Headache Foundation; consultant, advisory board member, or honoraria or research support from AbbVie/Allergan, Amgen, Axsome, Biohaven, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Merck, Novartis, Pfizer, Teva, Vector, and Vedanta Research; royalties from Wolff’s Headache, 8th edition (Oxford University Press, 2009) and Informa; stock/options in Axon, Biohaven, Cooltech, and Manistee. Robert Urman: employee and stockholder of Amgen Inc. Mark E. Bensink: was an employee of Amgen Inc. during study design and initiation and subsequently the Managing Director of Benofit Consulting, which received consulting fees from Amgen Inc. to support the interpretation of study results. Sarah C. Robinson, Shruti J. Vaidya, Alice S. Jacobson, Alexandra B. Scott, Alice R. Pressman: No conflicts of interest to declare.
: The study was approved by the Sutter Health Institutional Review Board. Informed consent was collected from the survey participants.
: Erenumab was codeveloped in partnership with Amgen Inc. and Novartis.
